A phase II study of laquinimod in Crohn's disease - Concepedia

Concepedia

Publication | Open Access

A phase II study of laquinimod in Crohn's disease

DOI Full Paper Access

79

Citations

14

References

2014

Year

Geert D’Haens, William J. Sandborn, Jean‐Frédéric Colombel, Paul Rutgeerts, Kurt Brown, Hadas Barkay, Anat Sakov, Asi Haviv, Brian G. Feagan

Abstract

NCT00737932.

References

	Year	Citations
A Short-Term Study of Chimeric Monoclonal Antibody cA2 to Tumor Necrosis Factor α for Crohn's Disease Stephan R. Targan, Stephen B. Hanauer, Sander J. H. van Deventer, New England Journal of Medicine	1997	3.1K
Infliximab for the Treatment of Fistulas in Patients with Crohn's Disease Daniel H. Present, Paul Rutgeerts, Stephan Targan, New England Journal of Medicine	1999	2.7K
Efficacy and safety of retreatment with anti–tumor necrosis factor antibody (infliximab) to maintain remission in Crohn's disease Paul Rutgeerts, Geert D’Haens, Stephan R. Targan, Gastroenterology InflammationChronic Inflammatory DiseasesAnti-inflammatoryImmunologyGastroenterology	1999	1.1K
The Prevalence and Geographic Distribution of Crohn’s Disease and Ulcerative Colitis in the United States Michael D. Kappelman, Sheryl L. Rifas‐Shiman, Ken Kleinman, Clinical Gastroenterology and Hepatology MedicineGastroenterologyGeographic DistributionClinical GastroenterologyGastrointestinal Pathology	2007	922
Fecal calprotectin is a surrogate marker for endoscopic lesions in inflammatory bowel disease Geert D’Haens, Marc Ferrante, Séverine Vermeire, Inflammatory Bowel Diseases	2012	797
Direct Health Care Costs of Crohn's Disease and Ulcerative Colitis in US Children and Adults Michael D. Kappelman, Sheryl L. Rifas‐Shiman, Carol Q. Porter, Gastroenterology Primary CareHealth EconomicsHealth PolicyHealth Care ReimbursementUs Children	2008	633
Placebo-Controlled Trial of Oral Laquinimod for Multiple Sclerosis Douglas Jeffery, Ludwig Kappos, Xavier Montalbán, New England Journal of Medicine	2012	356
Cost Analysis and Cost Determinants in a European Inflammatory Bowel Disease Inception Cohort With 10 Years of Follow-up Evaluation Selwyn Odes, Hillel Vardi, Michael Friger, Gastroenterology Health EconomicsFollow-up EvaluationGlobal HealthGastroenterologyOutcomes Research	2006	224
Laquinimod (ABR-215062) suppresses the development of experimental autoimmune encephalomyelitis, modulates the Th1/Th2 balance and induces the Th3 cytokine TGF-β in Lewis rats Jian-She Yang, Lingyun Xu, Bao‐Guo Xiao, Journal of Neuroimmunology InflammationAutoimmune DiseaseImmune Cell DevelopmentMedicineImmune Regulation	2004	175
Insight into the mechanism of laquinimod action Wolfgang Brück, Christiane Wegner Journal of the Neurological Sciences PhysiologyNeuroendocrine MechanismMechanism Of ActionNeuropharmacologyNeuroscience	2011	126

Page 1